Clinical Trials and Research

Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is a microangiopathy driven by the thromboinflammation of capillary beds and angiogenic revascularization…

Researchers have identified a common structure among toxic transthyretin (TTR) clumps, called amyloid fibrils, in heart tissue from people carrying mutations linked…

Cardiac amyloidosis, particularly transthyretin amyloidosis (ATTR) in older adults, is increasingly recognized as an important and potentially treatable cause of…

Background: Cardiac amyloidosis (CA) is an infiltrative restrictive cardiomyopathy characterized by the deposition of β-fold amyloid, often presenting as left…

ABSTRACTBackground and AimsHereditary transthyretin amyloidosis (ATTRv) is a multisystemic disease where early neuropathy signs are challenging to detect…

AbstractThe management of transthyretin amyloid cardiomyopathy (ATTR-CM) has revolved around the scintigraphic diagnosis since the introduction of a specific…

The safety and efficacy of vutrisiran are consistent with those observed in the overall population of East Asian patients treated in the phase 3 clinical trial…

Two Al algorithms from Anumana received FDA (US Food and Drug Administration) clearance in early2026 for something a standard 12-lead ECG has never been validated…

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced…

Study OverviewBrief SummarySystemic light chain amyloidosis (AL amyloidosis) is the most common type of systemic amyloidosis, with diverse clinical manifestations…